{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T08:40:08Z","timestamp":1752223208518,"version":"3.41.2"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>To describe the patterns of first prescription of antidiabetic drugs (AD) in patients with type 2 diabetes (T2D) and analyze the factors associated with the prescription of a modern one.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Observational longitudinal study conducted in the CArdiovascular Risk factors for HEalth Services research (CARhES) cohort. Individuals older than 15, resident in Arag\u00f3n (Spain), diagnosed with T2D during 2018\u20132022 were selected and followed-up until 31<jats:sup>st<\/jats:sup> December 2022. Secondary use of data from the health system provided sociodemographic, clinical and pharmacological prescription information. We also considered additional variables by Basic Healthcare Area (BHA) of residence. AD were classified into \u201cclassical\u201d and \u201cmodern\u201d and their differences were described and compared. A multilevel methodology stratified by sex was developed, considering individual characteristics and characteristics of the BHA of residence, to analyze the factors associated to a modern AD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Our population-based cohort of 22,892 patients were mostly male, native, low-income and living in non-depopulated BHA. People who were younger, with heart failure, ischemic heart disease, chronic renal failure, obesity, with a previous major adverse cardiovascular event, higher socioeconomic level or lived in less deprived and more depopulated areas were more likely to get a modern AD prescription.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our analyses showed that prescribing practices vary according to a range of sociodemographic, clinical and geographical characteristics. Knowledge of these factors is essential for implementing and improving equitable and person-centered approaches.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1530139","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T08:19:56Z","timestamp":1752221996000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors associated with prescription of modern antidiabetics in newly diagnosed patients with type 2 diabetes. a real-world data study in a Spanish region"],"prefix":"10.3389","volume":"16","author":[{"given":"Irantzu","family":"Bengoa-Urrengoechea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Aguilar-Palacio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jos\u00e9","family":"Rabanaque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Jes\u00fas","family":"Lallana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Gamba Cabezas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Malo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"dyae015","DOI":"10.1093\/ije\/dyae015","article-title":"Cohort profile: the CArdiovascular risk factors for hEalth services research (CARhES) cohort study","volume":"53","author":"Aguilar-Palacio","year":"2024","journal-title":"Int. J. Epidemiol."},{"key":"B2","first-page":"1","article-title":"Recomendaciones para el tratamiento de la diabetes mellitus tipo 2: control gluc\u00e9mico","volume":"2","author":"Alem\u00e1n","year":"2014","journal-title":"Algoritm Trat hiperglucemia diabetes tipo"},{"key":"B3","unstructured":"5 Gu\u00eda de diabetes tipo 2 para cl\u00ednicos: recomendaciones de la redGDPS\n          \n          \n            \n              Alem\u00e1n\n              J. J.\n            \n            \n              Men\u00e9ndez\n              S. A.\n            \n            \n              Lachica\n              L. \u00c1.\n            \n            \n              De La Puente\n              J. B.\n            \n            \n              Barutell\n              L.\n            \n            \n              Benito\n              B.\n            \n          \n          \n          2018"},{"key":"B4","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3122\/jabfm.2022.02.210360","article-title":"Prescription patterns of novel antihyperglycemic medications","volume":"35","author":"Ali","year":"2022","journal-title":"J. Am. Board Fam. Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s13300-022-01289-x","article-title":"An early assessment of the real-world treatment patterns of type 2 diabetes: a comparison to the 2018 ADA\/EASD consensus report recommendations","volume":"13","author":"Bae","year":"2022","journal-title":"Diabetes Ther."},{"key":"B6","first-page":"86","article-title":"Atenci\u00f3n Primaria comorbilidades de los pacientes cr\u00f3nicos seg\u00fan nivel","volume":"52","author":"Barrio-Cortes","year":"2020"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","article-title":"Fitting linear mixed-effects models using lme4","volume":"67","author":"Bates","year":"2015","journal-title":"J. Stat. Softw."},{"key":"B8","first-page":"1","article-title":"Spain: Health system review","volume":"26","author":"Bernal-Delgado","year":"2024","journal-title":"Health Syst. transition"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e002995","DOI":"10.1136\/bmjdrc-2022-002995","article-title":"Treatment pattern trends of medications for type 2 diabetes in British Columbia, Canada","volume":"10","author":"Carney","year":"2022","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"B10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196719","article-title":"Women are less likely than men to achieve optimal glycemic control after 1 year of treatment: a multi-level analysis of a Korean primary care cohort","author":"Choe","year":"2018"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e000729","DOI":"10.1136\/bmjdrc-2019-000729","article-title":"Effect of socioeconomic deprivation on outcomes of diabetes complications in patients with type 2 diabetes mellitus: a nationwide population-based cohort study of South Korea","volume":"8","author":"Choi","year":"2020","journal-title":"BMJ open diabetes Res. care"},{"key":"B12","first-page":"e201812087","article-title":"Construction of a deprivation index by basic healthcare area in Aragon using population and housing census 2011","volume":"92","author":"Comp\u00e9s Dea","year":"2018","journal-title":"Rev. Esp. Salud Publica"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphar.2021.807548","article-title":"Trends in antidiabetic drug discovery: FDA approved drugs, new drugs in clinical trials and global sales","volume":"12","author":"Dahl\u00e9n","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"B15","doi-asserted-by":"publisher","first-page":"155332","DOI":"10.1016\/j.metabol.2022.155332","article-title":"Pharmacotherapy of type 2 diabetes: an update and future directions","volume":"137","author":"DeMarsilis","year":"2022","journal-title":"Metabolism"},{"key":"B16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12939-022-01772-8","article-title":"Socio-economic inequalities in the use of drugs for the treatment of chronic diseases in Italy","volume":"21","author":"Di Filippo","year":"2022","journal-title":"Int. J. Equity Health"},{"key":"B17","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/1475-6773.13092","article-title":"Neighborhood disadvantage and chronic disease management","volume":"54","author":"Durfey","year":"2019","journal-title":"Health Serv. Res."},{"key":"B18","doi-asserted-by":"crossref","first-page":"e000376","DOI":"10.1136\/fmch-2020-000376","article-title":"GP prescribing in northern Ireland by deprivation index: retrospective analysis","volume":"8","author":"Frazer","year":"2020","journal-title":"Fam. Med. Community Heal"},{"key":"B19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.52102\/diabet\/pract.2023.2.art2","article-title":"Algoritmo de tratamiento de la diabetes mellitus tipo 2. RedGDPS 2023","volume":"14","author":"Garc\u00eda Soid\u00e1n","year":"2023","journal-title":"Diabetes pr\u00e1ctica"},{"key":"B20","doi-asserted-by":"publisher","first-page":"101509","DOI":"10.1016\/j.diabet.2024.101509","article-title":"Eleven-year trends in socioeconomic inequalities in the prevalence and incidence of pharmacologically treated type 2 diabetes in France, 2010\u20132020","volume":"50","author":"Guion","year":"2024","journal-title":"Diabetes Metab."},{"key":"B21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.pcd.2023.02.001","article-title":"Evaluation of SGLT-2 inhibitor treatment in type 2 diabetes patients with very high cardiovascular risk","volume":"17","author":"Hart","year":"2023","journal-title":"Prim. Care Diabetes"},{"key":"B22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"B23","first-page":"31","article-title":"IDF diabetes atlas","volume":"1","year":"2023","journal-title":"IDF Diabetes Atlas 10th Ed. 537 million people Worldw. have diabetes"},{"key":"B24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3803\/EnM.2023.1816","article-title":"Initial combination therapy in type 2 diabetes","volume":"39","author":"Kim","year":"2024","journal-title":"Endocrinol. Metab."},{"key":"B25","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1001\/jama.2022.13885","article-title":"Association of race and ethnicity with prescription of SGLT2 inhibitors and GLP1 receptor agonists among patients with type 2 diabetes in the veterans health administration system","volume":"328","author":"Lamprea-Montealegre","year":"2022","journal-title":"JAMA"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.socscimed.2011.11.036","article-title":"Place matters: neighborhood deprivation and cardiometabolic risk factors in the diabetes study of northern California (DISTANCE)","volume":"74","author":"Laraia","year":"2012","journal-title":"Soc. Sci. Med."},{"key":"B27","first-page":"41","article-title":"Actualizaci\u00f3n de 2020 del algoritmo de tratamiento de la hiperglucemia en la diabetes mellitus tipo 2 de la redGDPS","volume":"11","author":"Mata","year":"2020","journal-title":"Diabetes Pr\u00e1ctica"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e012463","DOI":"10.1136\/bmjopen-2016-012463","article-title":"Glycaemic control and antidiabetic treatment trends in primary care centres in patients with type 2 diabetes mellitus during 2007-2013 in Catalonia: a population-based study","volume":"6","author":"Mata-Cases","year":"2016","journal-title":"BMJ Open"},{"key":"B29","doi-asserted-by":"crossref","first-page":"523.e1","DOI":"10.1016\/j.recesp.2021.11.027","article-title":"Gu\u00eda ESC 2021 sobre el diagn\u00f3stico y tratamiento de la insuficiencia cardiaca aguda y cr\u00f3nica","volume":"75","author":"McDonagh","year":"2022","journal-title":"Rev. Espa\u00f1ola Cardiol."},{"key":"B30","unstructured":"Depression, neighborhood deprivation and risk of type 2 diabetes\n          \n          \n            \n              Mezuk\n              B.\n            \n            \n              Chaikiat\n              \u00c5.\n            \n            \n              Li\n              X.\n            \n            \n              Sundquist\n              J.\n            \n            \n              Kendler\n              K. S.\n            \n            \n              Sundquist\n              K."},{"key":"B31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2337\/dc17-1414","article-title":"Long-term trends in antidiabetes drug usage in the U.S.: real-World evidence in patients newly diagnosed with type 2 diabetes","volume":"41","author":"Montvida","year":"2018","journal-title":"Diabetes Care"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.3390\/ijerph17103742","article-title":"Initial therapy, regimen change, and persistence in a Spanish cohort of newly treated type 2 diabetes patients: a retrospective, observational study using real-world data","volume":"17","author":"Moreno-Juste","year":"2020","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B33","doi-asserted-by":"publisher","first-page":"912","DOI":"10.3390\/medicina60060912","article-title":"Hypoglycemic drugs in patients with diabetes mellitus and heart failure: a narrative review","volume":"60","author":"Nikolaidou","year":"2024","journal-title":"Med. (B Aires)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"110777","DOI":"10.1016\/j.diabres.2023.110777","article-title":"Longitudinal treatment patterns in patients recently diagnosed with type 2 diabetes mellitus in Catalonia","volume":"202","author":"Ouchi","year":"2023","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B35","doi-asserted-by":"crossref","first-page":"m4573","DOI":"10.1136\/bmj.m4573","article-title":"Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"372","author":"Palmer","year":"2021","journal-title":"BMJ"},{"key":"B36","doi-asserted-by":"publisher","first-page":"658","DOI":"10.7326\/M23-2788","article-title":"Newer pharmacologic treatments in adults with type 2 diabetes: a clinical guideline from the American college of physicians","volume":"177","author":"Qaseem","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"B37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-59643-7","article-title":"Incidence of diabetes mellitus in Spain as results of the nation-wide cohort di@bet.es study","volume":"10","author":"Rojo-Mart\u00ednez","year":"2020","journal-title":"Sci. Rep."},{"key":"B38","volume-title":"Spanish ministry for the ecological transition and the demographic challenge","year":"2023"},{"key":"B39","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s41581-022-00535-6","article-title":"Kidney and heart failure outcomes associated with SGLT2 inhibitor use","volume":"18","author":"van der Aart-van der Beek","year":"2022","journal-title":"Nat. Rev. Nephrol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.clinthera.2019.05.003","article-title":"Treatment patterns in patients with newly diagnosed type 2 diabetes in China: a retrospective, longitudinal database study","volume":"41","author":"Wang","year":"2019","journal-title":"Clin. Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12933-023-02032-x","article-title":"Recent UK type 2 diabetes treatment guidance represents a near whole population indication for SGLT2-inhibitor therapy","volume":"22","author":"Young","year":"2023","journal-title":"Cardiovasc Diabetol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1530139\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T08:20:00Z","timestamp":1752222000000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1530139\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":42,"alternative-id":["10.3389\/fphar.2025.1530139"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1530139","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"article-number":"1530139"}}